Expanding its presence in oncology, Eli Lilly has entered into an agreement to acquire Point Biopharma in a deal worth up to US$1.4 B. Through this deal, Lilly will be able to access Point’s pipeline of clinical and preclinical stage radioligand therapies in development for the treatment of cancer, as well as its radiopharmaceutical manufacturing and R&D campuses. The collaboration has the potential to significantly accelerate the discovery, development and global access to radiopharmaceuticals.